Summit Therapeutics SMMT Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's accounts payable?
- Summit Therapeutics (SMMT) reported accounts payable of $27.55M in Q1 2026.
- How has Summit Therapeutics's accounts payable changed year-over-year?
- Summit Therapeutics's accounts payable increased by 451.6% year-over-year, from $4.99M to $27.55M.
- What is the long-term trend for Summit Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Summit Therapeutics's accounts payable has grown at a 27.0% compound annual growth rate (CAGR), from $6.14M to $20.29M.
- What does accounts payable mean?
- Money the company owes to its suppliers for goods and services received.
- How do you interpret accounts payable?
- An increase may suggest improved cash management or delayed payments, while a decrease indicates faster settlement of supplier obligations.
- How does accounts payable compare across companies?
- Standard across all industries; biotechs often show fluctuations based on clinical trial milestones and procurement cycles.